



Media Release

Production resumed as usual at Company's Unit post major fire reported at Mahad MIDC

No loss to life or any injury at Lasa Unit

All hard assets intact with no major impact

Assets covered under appropriate insurance

Mumbai, May 2, 2018: Lasa Supergenerics Limited (BSE: 540702, NSE: LASA), pioneer and among the leading players in manufacturing of Veterinary APIs in India through its catalyst chemistry expertise and fully backward integrated unit, would like to inform that production has resumed as usual at its Mahad Unit, post the major fire that was reported last week, in Mahad MIDC.

There was a fire incident reported at one of the companies located at MIDC, Mahad on 26th April'18, since the fire was major the entire area within 2 km radius was strictly evacuated by regulatory authorities without any prior intimation for safety reasons which resulted into halt on entire operations including those running batches in process and as per company's policy on determination of materiality this event was disseminated in public.

However, the orphaned batches in process were also been successfully rescued by our team of experts with no loss of yield and purity of product.

The Company has not suffered any operational loss and loss to life or injury also all the hard assets are intact with no major impact.

Moreover, Company has all the insurance policies in place which includes Business Interruptions/ Material Damage/ Fire/ Loss of Profit/ Natural Calamities etc. to deal with such incidents.

This unit located at MIDC, Mahad is used for making Veterinary APIs.



Management Comment:

Commenting on the recent development, Mr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said:

"We are happy to inform that the Company has resumed its production at Mahad Unit post a major fire reported in Mahad MIDC. All the hard assets are intact and are adequately covered under appropriate insurance. There was no loss to life or property reported. The safety and health of our people has always been our prime focus and we are thankful that no one was hurt or injured at our unit.

I would like to thank the entire team of 'LASA' for staying together and working in such unforeseen circumstances. Their untiring efforts, hard work, sincerity and high dedication give a great strength to 'LASA' to overcome such incidents."

About Lasa Supergenerics Limited:

Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. The Company is a pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. It specializes in 'catalyst chemistry' and manufactures anthelmintic / veterinary API. To efficiently control the supply chain, the company has backward integrated its key molecules. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra. The Company exports APIs to countries like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more details please visit: www.lasalabs.com

For any Investor Relations query, please contact:

Dr. Omkar Herlekar Chairman & MD Lasa Supergenerics Limited Email: investor@lasalabs.com	Savli Mangle Bridge Investor Relations Pvt. Ltd. Phone: +91-22-26873003 Email: savli@bridge-ir.com
---	--

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*